Stephen Liu, MD, on the Impact the IMpower010 Trial at ASCO 2021


At ASCO 2021, Stephen Liu, MD, discussed his excitement for results of the IMpower010 trial of atezolizumab in patients with early-stage resected non–small cell lung cancer

CancerNetwork® sat down with Stephen Liu, MD, of the Georgetown Lombardi Comprehensive Cancer Center, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to talk about the results of the phase 3 IMpower010 trial (NCT02486718) of atezolizumab (Tecentriq) versus best supportive care for the treatment of patients with stage IB to IIIA surgically resected non–small cell lung cancer.


I think at ASCO 2021, the one abstract we’re really waiting to see and the results that we want to pour over are the results from IMpower010. This is the adjuvant study of atezolizumab and the first study showing us a benefit with immunotherapy after surgical resection compared with placebo in a randomized trial. Looking at immunotherapy for patients with completely resected non–small cell lung cancer after chemotherapy and immunotherapy has been a transformative treatment for metastatic lung cancer. We also know that for patients with resected lung cancer, while our goal is cure, it’s not always our expectation. Lung cancer is a very difficult disease to eradicate. Implementing immunotherapy in that setting really can improve our outcomes and extend the cure to more people coupled with earlier detection and screening. I think this has a chance to make a huge impact for patients with lung cancer.


Wakelee HA, Altorki NK, Zhou C, et al. IMpower010: primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(suppl 15):8500. doi:10.1200/JCO.2021.39.15_suppl.8500

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
A panel of 3 experts on lung cancer
A panel of 3 experts on lung cancer
A panel of 3 experts on lung cancer
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Related Content